13F Holdings
中文EN

CLDI Calidi Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1855485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.9%
TTM EPS YoY192.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-373.6%
ROA-163.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets70.5%
Debt / equity0.41x
Current ratio1.27x
Interest coverage-252.18x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.70M$2.56M$2.59M$2.36M$2.36M$2.59M$2.42M$1.81M
SG&A expense$1.64M$1.59M$1.60M$2.11M$2.69M$3.07M$2.64M$2.21M
Operating income-$4.34M-$4.15M-$4.19M-$4.47M-$5.05M-$5.66M-$5.06M-$4.03M
Interest expense$23,000$22,500$22,500$0$27,000$40,000$100,000$100,000
Pretax income-$3.64M-$4.16M-$4.10M-$4.06M-$5.17M-$5.76M-$5.06M-$4.14M
Income tax$9,000$5,000$4,000-$2,000$10,000$4,000$3,000$3,000
Net income-$3.65M-$4.16M-$4.11M-$4.06M-$5.15M-$5.71M-$4.99M-$4.10M
EBITDA-$3.93M-$3.71M-$3.76M-$4.04M-$4.62M-$4.95M-$4.67M-$3.63M
EPS (basic)-1.47-2.94-0.43—-35.25-31.75-2.21—
EPS (diluted)-1.47-2.94-0.43—-35.25-31.75-2.21—
Weighted avg. shares (diluted)2.48M1.42M10.31M—307,000180,0002.26M—
Balance sheet
Cash & equivalents$4.17M$4.29M$6.85M$5.82M$10.59M$5.38M$10.78M$9.81M
Current assets$4.74M$5.43M$7.35M$6.26M$11.03M$6.05M$11.49M$10.23M
PP&E, net$704,000$775,000$758,000$781,000$849,000$929,000$795,000$869,000
Total assets$5.52M$7.20M$9.59M$8.86M$14.03M$9.35M$15.06M$14.18M
Current liabilities$3.73M$3.24M$3.84M$3.94M$5.19M$5.35M$5.43M$9.50M
Short-term debt$668,000$45,000$23,000$90,000$472,000$820,000$1.16M$3.22M
Long-term debt$0$600,000$600,000$600,000$600,000$600,000$600,000$600,000
Total debt$668,000$645,000$623,000$690,000$1.07M$1.42M$1.75M$3.82M
Total liabilities$3.89M$4.07M$4.66M$5.10M$6.83M$7.28M$7.76M$12.21M
Shareholders' equity$1.63M$3.13M$4.93M$3.76M$6.92M$1.76M$6.94M$1.53M
Net debt-$3.50M-$3.65M-$6.23M-$5.13M-$9.52M-$3.96M-$9.02M-$5.99M
Shares outstanding2.89M2.08M11.79M451,0766.91M2.88M31.79M1.73M
Cash flow statement
Operating cash flow-$2.34M-$4.35M-$4.12M-$5.04M-$4.24M-$4.88M-$7.13M-$5.42M
Investing cash flow-$23,000-$33,000-$5,000-$79,000-$27,000-$57,000-$7,000-$5,000
Financing cash flow$2.25M$1.83M$5.16M$340,000$9.48M-$469,000$8.11M$13.11M
Depreciation & amortization$417,000$438,000$426,000$423,000$427,000$710,000$394,000$393,000
Stock-based compensation$62,000$157,000$231,000$450,000$529,000$522,000$607,000$626,000

Free plan shows the latest 8 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.